*All Times Shown are in Eastern Daylight Time*

8:00 am Virtual Coffee & Networking

Revealing the Latest Updates From a Year in IPF Drug Development
Plenary Moderator: Fernando Martinez, Chief Division of Pulmonary and Critical Care Medicine, Cornell

8:30 am Overview of the Latest IPF Drug Development Research

  • Fernando Martinez Chief Division of Pulmonary & Critical Care Medicine , Cornell University


  • Reviewing the latest updates in IPF drug development
  • Understanding the current challenges facing IPF drug developers
  • Looking to the future – what will IPF drug development look like in a post COVID world?

9:00 am Developing Novel Therapies: Uncovering the PF Connectome

  • Naftali Kaminski Professor of Internal Medicine, Yale University School of Medicine


  • Understanding the PF Connectome and what it means for IPF drug developers
  • Utilizing artificial intelligence and cutting-edge, single cell profiling technologies to accelerate implementations of novel precision therapies in PF
  • Creating a dynamic, public atlas of cell and compound fibrosis specific signatures

9:30 am A Novel Murine Model of Pulmonary Fibrosis: The Role of Platelets in Chronic Changes Induced by Bleomycin

  • Steven Jordan Associate Director, Pharmacology Department, Labcorp


• Hear how the study established a novel model of
pulmonary fibrosis where we could investigate changes in
lung function and histology
• Learn how we utilized this model to investigate the role of
platelets in pulmonary fibrosis
• As we explain a novel model of pulmonary fibrosis that is
associated with a decline in lung function similar to the
clinical setting

10:00 am Speed Networking


This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the IPF field and establish meaningful business relationships to pursue for the rest of the conference, all from the comfort of your own home or office.

10:30 am Morning Break & Networking

Preclinical & Early Translational Track

Late Translational & Clinical Track

Deep Dive into IPF Models

Track Moderator: Jane Connor, Associate Director, AstraZeneca 

Analyzing Key IPF Clinical Trial Updates

Track Moderator: Robert Kaner, MD, Cornell University

11.00 Investigating Novel Tools & Technologies to Improve IPF Models

Jesse Roman, Ludwig Kind Professor of Medicine and Pharmacology, Thomas Jefferson University

11.00 Understanding the value of Handheld Spirometry in Clinical Trials

Courtney Schiffman, Senior Statistical Scientist, Genentech

11.30 Exploring Myeloid Cells in Animal Models of Lung Fibrosis

Bethany Moore, Chair-Microbiology & Immunology, University of Michigan

11.30 Understanding What Factors to Consider When Incorporating Existing Drugs in IPF Clinical Trial Design

Martin Kolb, Director at the Division of Respirology, McMaster University

12.00 Delving into the Mechanistic & Therapeutic Relevance of Humanized Models to Understand Their Translational Potential in IPF Drug Development

Lee Borthwick, Professor, University of Newcastle 

12.00 End of Track

12:30 pm Lunch & Networking

Preclinical & Early Translational Track

Late Translational & Clinical Track

Deep Dive into IPF Models

Track Moderator: Jane Connor, Associate Director, AstraZeneca 

Analyzing Key IPF Clinical Trial Updates

Track Moderator: Robert Kaner, MD, Cornell University

1.30 Reviewing the Relationship Between IPF & Cancer – What do You Need to Know from a Drug Development Perspective?

Timothy Blackwell, Professor, Vanderbilt University

1.30 Audience Discussion: Utilizing Lessons Learned from Failed IPF Clinical Trials to Take Decisive Action & Translate Pre-Clinical Success into Clinical Success for Your IPF Drug

Martin Kolb, Director at the Division of Respirology, McMaster University

2.00 Investigating Lessons Learned from Humanized Monoclonal Antibodies in Pancreatic Cancer and Renal Fibrosis for IPF Drug Development

Lewis Gruber, Chief Scientific Officer, Siwa Therapeutics 

2.00 Exploring Patient Reported Outcomes from a Regulatory Standpoint & Learning How to Ensure the Outcomes You Use Today Facilitate Therapeutic Approval in the Future

Jeff Swigris, Professor, National Jewish Health

2.30 Highlighting Discovery and Preclinical In Vivo Efficacy in a Bleomycin-induced model of IPF for two compounds with novel MOAs identified using two XAR’s proprietary AI-platform?

Anjali Pandey, Senior Vice President, Nonclinical and Chemistry

2.30 Latest Update on Pliant’s IPF Research

Greg Cosgrove, Vice President Clinical Development, Pliant Therapeutics 

3.00 Pharmacological Mobilization of Innate Immune Response to Prevent and Treat IPF in Preclinical Models

Andrei Gudkov, Chief Science Officer, Genome Protection


3.00 The Role of LTI-03 in Lung Fibrosis

Cory Hoagaboam, Senior Medical Director, Lung Therapeutics

3:30 pm Afternoon Break & Networking

Exploring Emerging Therapeutics & Treatment Strategies for IPF
Chair speaker for afternoon plernary sessions: Jessica Shore, Vice President – Research & Programs, Pulmonary Fibrosis Foundation

4:00 pm Discovering a Therapeutic Approach for IPF Utilizing Inhaled Antisense Oligonucleotides

  • Jeff Crosby Director of Pulmonary Drug Discovery , Ionis Pharmaceuticals


  • Investigating antisense as therapy for pulmonary fibrosis
  • Optimizing antisense therapeutic design for targeting various cell types in lung
  • Evaluating antisense inhibitors in mouse models of IPF

4:30 pm Revealing Potent & Selective Human Prostaglandin F (FP) Receptor Antagonist BAY-6672 for Idiopathic Pulmonary Fibrosis (IPF)

  • Hartmut Beck Bayer Science Fellow & Laboratory Head of Medicinal Chemistry , Bayer Pharmaceuticals


  • Antagonism of the FP Receptor as a promising new antifibrotic target for the treatment of IPF
  • From screening hit to BAY-6672: a successful multifactorial small molecule optimization story
  • BAY-6672 is now available as donated chemical probe via the Structural Genomics Consortium (SGC

5:00 pm Investigating How to Manipulate Metabolic Reprogramming for IPF Treatment

  • Min Lu Senior Director & Head of Fibrosis, Morphic Therapeutics


  • An overview of the metabolic context of IPF
  • Comprehensively analyzing the relationship between IPF patient phenotype and underlying metabolic disease
  • Hearing how to address factors such as obesity, glucose intolerance, insulin resistance and diabetes in a pre-clinical setting for IPF drug development

5:30 pm Multiple mechanisms for Collagen mRNA translation regulation in IPF: from mRNA processing to mRNA translation


• Translation Control Therapeutics platform for the discovery of small
molecule mRNA drugs
• The selectivity of COL1A1 regulation across tissues allowing for tissue
selective drugs
• In vivo studies: from prevention to treatment paradigms

6:00 pm End of Day One